Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with s...See more
Headquarter United States of America |
Countries of operation United States of America, Singapore |
Year founded 1999 (25 years) |
Funding status Publicly listed on stock exchange |
Company type MNC / Large Enterprise |
Administrative Assistant